DBV Technologies moves into new buildings to meet its growth and international development needs
Download official press release (201.1 KB)
Bagneux, September 21, 2011 - DBV TECHNOLOGIES French biotechnology company developing a unique therapeutic approach in the treatment of food allergy. This method by cutaneous route is innovative, simple and safe. It allows for the treatment of peanut allergy, which claims numerous victims each year. To meet its growth needs and the strong recruitment of new employees serving its new developments, DBV TECHNOLOGIES moves into new facilities at Bagneux (Hauts de Seine Department) and now benefits from ultra-modern facilities responding to recent environmental standards. With 1500 m² premises, the company has now scientific and technical laboratories measuring up to its international ambitions.
This move marks a new milestone for DBV TECHNOLOGIES after the fundraising of 19.4 M€ completed in December 2010 with Innobio (ISP), Lundbeckfond Ventures, Shire and Alto Invest, together with Sofinnova Partners, lead-investor and historical shareholder of ALK Abello, in capital since 2009.
